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Neurovascular coupling (NVC) is the temporal link between neuronal metabolic activity
and regional cerebral blood flow (CBF), supporting adequate delivery of nutrients.
Exposure to high altitude (HA) imposes several stressors, including hypoxia and
hypocapnia, which modulate cerebrovascular tone in an antagonistic fashion. Whether
these contrasting stressors and subsequent adaptations affect NVC during incremental
ascent to HA is unclear. The aim of this study was to assess whether incremental
ascent to HA influences the NVC response. Given that CBF is sensitive to changes
in arterial blood gasses, in particular PaCO2, we hypothesized that the vasoconstrictive
effect of hypocapnia during ascent would decrease the NVC response. 10 healthy study
participants (21.7 ± 1.3 years, 23.57 ± 2.00 kg/m2, mean ± SD) were recruited as part
of a research expedition to HA in the Nepal Himalaya. Resting posterior cerebral artery
velocity (PCAv), arterial blood gasses (PaO2, SaO2, PaCO2, [HCO3−], base excess
and arterial blood pH) and NVC response of the PCA were measured at four pre-
determined locations: Calgary/Kathmandu (1045/1400 m, control), Namche (3440 m),
Deboche (3820 m) and Pheriche (4240 m). PCAv was measured using transcranial
Doppler ultrasound. Arterial blood draws were taken from the radial artery and analyzed
using a portable blood gas/electrolyte analyzer. NVC was determined in response to
visual stimulation (VS; Strobe light; 6 Hz; 30 s on/off × 3 trials). The NVC response was
averaged across three VS trials at each location. PaO2, SaO2, and PaCO2 were each
significantly decreased at 3440, 3820, and 4240 m. No significant differences were
found for pH at HA (P > 0.05) due to significant reductions in [HCO3−] (P < 0.043). As
expected, incremental ascent to HA induced a state of hypoxic hypocapnia, whereas
normal arterial pH was maintained due to renal compensation. NVC was quantified as
the delta (1) PCAv from baseline for mean PCAv, peak PCAv and total area under
the curve (1PCAv tAUC) during VS. No significant differences were found for 1mean,
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1peak or 1PCAv tAUC between locations (P > 0.05). NVC remains remarkably intact
during incremental ascent to HA in healthy acclimatized individuals. Despite the array of
superimposed stressors associated with ascent to HA, CBF and NVC regulation may
be preserved coincident with arterial pH maintenance during acclimatization.
Keywords: neurovascular coupling, hypoxia, hypocapnia, high-altitude, cerebral blood flow
INTRODUCTION
High altitude (HA) presents several stressors, both environmental
and physiological, to normal human function and survival.
Environmental stressors can include, but are not limited to,
severe winds, cold temperatures and decreases in barometric
pressure. Due to reductions in barometric pressure, total
oxygen availability decreases. Consequential physiological
stressors include hypoxia, ventilatory-induced hypocapnia
and acid-base disturbances. These stressors drive several
physiological adaptations to preserve homeostasis (e.g.,
ventilatory acclimatization). This dynamic relationship between
stressor and adaptation has inspired scientific research for
generations into the exact mechanisms and pathways responsible
for maintaining homeostasis and health at HA.
In normal circumstances the human brain accounts for only
2% of total body weight, and yet is responsible for 20% of
total energy consumption within the body (Attwell et al., 2011;
Bor-Seng-Shu et al., 2011; Subudhi et al., 2014). Brain tissue
possesses a high RMR, with limited capacity for glycogen storage
(Brown and Ransom, 2007; Willie et al., 2014). Consequently,
the cerebrovasculature requires tight, narrow control of CBF
for the delivery of nutrients and removal of metabolic wastes
(Drake and Iadecola, 2007; Lecrux and Hamel, 2011). The brain
maintains adequate CBF during instances of increased neuronal
metabolic demand due to high vascularisation and a sophisticated
regulation of rCBF (Phillips et al., 2016).
Regarding the cerebrovasculature, many studies have shown
that acute exposure to HA induces an increase in gCBF,
with values returning to sea-level during acclimatization
(Severinghaus et al., 1966; Møller et al., 2002; Lucas et al., 2011).
This response stems from the vasodilatory effect of hypoxia below
a certain threshold (<40–45 mmHg) (Brugniaux et al., 2007;
Ainslie and Ogoh, 2010; Willie et al., 2014; Flück et al., 2015). The
increase in gCBF is crucial to maintain CDO2 at HA (Hoiland
et al., 2016). CDO2 is a product of gCBF and arterial oxygen
content (Subudhi et al., 2014). gCBF increases during exposure to
Abbreviations: ABGs, arterial blood gases; AMS, acute mountain sickness; BMI,
body mass index; CBF, cerebral blood flow; CDO2, cerebral oxygen delivery; DBP,
diastolic blood pressure; ECG, electrocardiogram; gCBF, global cerebral blood flow;
HA, high altitude; Hb, hemoglobin; HCO3−, bicarbonate; Hct, hematocrit; HR,
heart rate; HVR, hypoxic ventilatory response; MAP, mean arterial pressure; NVC,
neurovascular coupling; P(ET )CO2, partial pressure of end-tidal carbon dioxide;
PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial
oxygen; PATM , total atmospheric pressure; PCA, posterior cerebral artery; PCAv,
posterior cerebral artery velocity; PIO2, Partial pressure of inspired oxygen; rCBF,
regional cerebral blood flow; RMR, resting metabolic rate; SaO2, arterial oxygen
saturation; SBP, systolic blood pressure; SpO2, Peripheral oxygen saturation; tAUC,
total area under the curve; TCD, transcranial doppler ultrasound; VS, visual
stimulation.
HA to compensate for the decrease in PaO2, maintaining CDO2
(Hoiland et al., 2016).
Although research into the effects of HA on CBF is
comprehensive, the impact of ascent to HA on the control of
CBF, per se, is less well understood. CBF is controlled via three
distinct mechanisms: cerebrovascular reactivity to alterations in
blood gasses, cerebral autoregulation in response to changes
in perfusion pressure, and NVC. NVC pertains to the tight
regulation between local neuronal activity and increased regional
CBF (rCBF) (Caldwell et al., 2018). NVC is controlled via the
interplay between astrocytes, neurons and microvessels within
the cerebrovasculature (endothelial cells and pericytes) (Girouard
and Iadecola, 2006; Filosa et al., 2016; Venkat et al., 2016). Each
of these work in concert with one another by eliciting a vasoactive
effect on local microvessels within the cerebrovasculature.
A validated method of evoking an NVC response is via VS
of the occipital lobe (Phillips et al., 2016). The resultant NVC
response can be monitored by assessment of the PCA using
TCD (Willie et al., 2011). TCD provides beat-by-beat changes
in cerebral blood velocity among other parameters to assess the
signal-flow coupling relationship. Acclimatization to HA and
its influence on NVC is complex due to multiple contrasting
stimuli. Exposure to hypoxia results in hypoxic vasodilation.
However, hypoxia triggers the HVR (Teppema and Dahan, 2010).
The HVR manifests increased ventilatory drive raising PaO2
levels with concomitant decreases in PaCO2 (hypocapnia). The
resultant hypocapnia is a potent vasoconstrictor (Wilson et al.,
2009). The cerebrovasculature is particularly sensitive to changes
in ABGs, especially PaCO2 (Brugniaux et al., 2007; Ainslie and
Ogoh, 2010). Previous literature shows that as little as a 1 mmHg
increase or decrease from normal PaCO2 levels results in a 3–6%
increase or 1–3% decrease in gCBF, respectively (Willie et al.,
2014; Phillips et al., 2016). Whether one of these competing
stressors elicits a dominant effect on vessel reactivity to stimulus
at HA is intriguing as laboratory-based research has shown
that hypocapnia reduces NVC response magnitude (Szabo et al.,
2011).
The impact of incremental ascent to HA on NVC remains
unclear. To our knowledge, only one other study has directly
investigated the effect of HA on the NVC response (Caldwell
et al., 2017). Caldwell and colleagues observed no significant
effects of HA on the NVC response, comparing sea-level
measures for NVC to multiple days (3 and 7 days) at one
specific altitude (3800 m). We wished to address the issue
by way of an incremental ascent profile to a higher altitude
(4240 m). We investigated the effects of four progressively
increasing altitudes on the NVC response making direct
comparisons between altitudes, within-individuals. In
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FIGURE 1 | Ascent profile. An illustration of the expedition ascent profile. The
days spent at each location are presented on the x-axis with the
corresponding altitude of each location presented on the y-axis. Arrows
denote measurement location/dates.
addition, we determined ABGs and acid-base status during
ascent to characterize the acclimatization process. Given that
cerebrovascular tone is superiorly sensitive to changes in PaCO2
compared with PaO2, we hypothesized that the vasoconstrictive
effect of hypocapnia would reduce the NVC response with
ascent.
MATERIALS AND METHODS
Participants and Ethical Approval
Ten study participants were recruited as part of a 21-day research
expedition to Everest base camp in the Nepal Himalaya. The
expedition was considered a low-risk ascent profile (Zuckerman,
2012; see Figure 1 for ascent profile). All participants had no
prior-history of cardiovascular, respiratory or cerebrovascular
disease. Nine subjects were residents of Calgary (1045 m).
One subject was an Irish national (0 m; sea-level) who had
been living in Calgary for 5 months prior to the expedition.
Several over-the-counter medications were taken during ascent,
predominantly as a method of curtailing symptoms associated
with exposure to HA (headache, diarrhea, cough, flu-like
symptoms). The medications used were: Imodium, Ibuprofen,
Neocitran, Advil, Pepto bismal and DM expectant syrup. Several
of the female participants were taking oral contraception (Yasmin
and Tricylen-lo) during the expedition. Diamox (acetazolamide)
was not taken by any participant at any time during the
ascent.
This study abided by the Canadian Government Tri-Council
policy on research ethics with human participants (TCPS2) and
conformed with the standards set by the latest revision of the
Declaration of Helsinki, except for registration in a database.
Ethical approval was received in advance through the Mount
Royal University Human Research Ethics Board (Protocols
100012 and 100922) and was harmonized with the Nepal
Health Research Council (Protocol 109-2017). All participants
were recruited via verbal communication and all provided
written and informed consent prior to voluntary participation
in the study. Although this study took place in the context
of a large research expedition to altitude, the specific study
design, research question and data collection were planned
a priori.
Physiological Measures
Posterior cerebral artery blood velocity (PCAv) and NVC
response were assessed and later compared between Calgary
(1045 m), Namche (3440 m), Deboche (3820 m), and Pheriche
(4240 m). Similarly, arterial blood gasses (ABGs; PaO2, SaO2,
PaCO2, arterial bicarbonate [HCO3−], base excess and arterial
pH) were collected at the same pre-determined locations as
PCAv and NVC. Most baseline ABGs were collected at 1045 m.
However, two participants had their baseline ABGs taken at
Kathmandu (1400 m) due to logistical issues. Therefore, when
describing ABGs within the results section we have referred to
1045 m/1400 m as baseline.
A total of 3 days were spent in Kathmandu (1400 m) prior to
beginning the expedition. In addition to NVC, PCAv, and ABGs,
several daily measures were obtained each morning, beginning
in Kathmandu and continued for the duration of the expedition.
The measures collected each morning were: HR, arterial blood
pressure (Systolic; SBP, Diastolic; DBP), pressure of end-tidal
CO2 [(PET)CO2], peripheral oxyhemoglobin saturation (SpO2),
Hb and hematocrit (hct) (see Table 1).
During ascent, participants spent a total of 2 days at each
rest day altitude (3440, 3820, and 4240 m). The 1st day
consisted of arrival having trekked from the preceding lower
altitude, with recovery from the trek and one night’s sleep
at the new altitude. The 2nd day consisted of data collection
and an overnight stay before further ascent beginning the
following morning. PCAv, NVC and ABGs were measured
on the 2nd day at each altitude. This was implemented
to reduce the possible effects of recent exercise on each
variable. Participants were also tested sequentially in an identical
fashion for PCAv and NVC at each location to account
for the possible effects of circadian rhythm on cerebral
hemodynamics.
Instrumentation
Daily Measures and Arterial Blood Draws
Each morning (06:00–08:00), non-invasive fasted daily measures
were made including weight (digital scale; Omron, model
OMRHBF514C), Hb concentration (hemoglobinometer;
Hemocue HB201+) and hematocrit (hct; heparinized capillary
tube, mini-centrifuge; StatSpin, CritSpin microhematocrit
system, Model M960). The participant was seated in a private
and quiet room and provided with white noise through head
phones to minimize distraction. Subsequently, respiratory rate
and (PET)CO2 were measured using a portable, calibrated
capnograph (Masimo EMMA, Danderyd, Sweden) with a
personal mouthpiece and nose clip. HR and SpO2 were measured
with a portable finger pulse oximeter (Masimo SET R© Rad-5,
Danderyd, Sweden). Arterial blood pressure (i.e., systolic,
diastolic) was measured using an automated blood pressure cuff
(Omron, model BP786n) and used to calculate pulse pressure
(systolic-diastolic) and MAP (1/3 systolic + 2/3 diastolic).
Frontiers in Physiology | www.frontiersin.org 3 November 2018 | Volume 9 | Article 1691
fphys-09-01691 November 27, 2018 Time: 12:44 # 4
Leacy et al. Neurovascular Coupling at High Altitude
TABLE 1 | Daily measures.
Daily measures
1400 m 3 440 m 3820 m 4240 m
Baseline P-value P-value P-value
P(ATM) 648 509 – 486 – 454 –
PIO2 (mmHg) 136 107 – 102 – 95 –
AMS 0(2) 1(3) – 0(4) – 1(3) –
Weight (kg) 71.31 ± 14.49 70.30 ± 13.69 P = 0.160 70.23 ± 13.68 P = 0.126 70.23 ± 13.34 P = 0.237
BMI (kg/m2) 23.57 ± 2.00 23.35 ± 1.84 P = 0.757 23.33 ± 1.84 P = 0.515 23.34 ± 1.78 P = 0.826
Systolic (mmHg) 112.50 ± 10.77 116.40 ± 8.32 P = 1.000 119.40 ± 10.98 P = 0.154 118.70 ± 10.68∗ P < 0.001
Diastolic (mmHg) 77.90 ± 11.05 86.60 ± 8.41∗ P = 0.001 89.60 ± 10.45∗ P = 0.002 87.40 ± 9.42∗ P = 0.001
MAP (mmHg) 89.43 ± 10.63 96.39 ± 7.32∗ P = 0.026 99.53 ± 10.13∗ P = 0.006 97.83 ± 9.27∗ P < 0.001
HR (bpm) 85.90 ± 8.85 91.60 ± 13.92 P = 0.473 84.10 ± 7.49 P = 0.100 84.90 ± 10.90 P = 0.100
SpO2 (%) 96.40 ± 0.97 91.80 ± 2.49∗ P = 0.005 91.40 ± 2.84∗ P = 0.005 87.60 ± 2.01∗† P = 0.005
P(ET)CO2 (Torr) 32.60 ± 6.77 26.50 ± 2.99∗ P = 0.043 25.30 ± 2.67∗ P = 0.018 21.10 ± 1.91∗†U P = 0.001
Daily measures collected each day, beginning in Kathmandu (1400 m). BMI, body mass index; MAP, mean arterial pressure; HR, heart rate; SpO2, peripheral oxygen
saturation; P(ET)CO2, partial pressure of end-tidal CO2; P(ATM), total atmospheric pressure; PIO2, partial pressure of inspired oxygen; AMS, acute mountain sickness
score. The exact p-value comparing each altitude to baseline is provided. ∗ = Statistical significance from 1400 m. † = Statistical significance from 3440 m. U = Statistical
significance from 3820 m. NS = non-significant (P > 0.05). Presented as mean ± SD, AMS data are presented as median (range).
TABLE 2 | Arterial blood gas and acid-base status.
Arterial blood draws
1045/1400 m 3440 m 3820 m 4240 m
Baseline P-value P-value P-value
PaO2 (mmHg) 84.80 ± 5.35 48.56 ± 8.08∗ P < 0.001 54.56 ± 6.23∗ P < 0.001 48.38 ± 4.96∗ P < 0.001
SaO2 (%) 96.80 ± 0.79 84.89 ± 7.87∗ P = 0.032 88.78 ± 3.73∗ P = 0.003 85.50 ± 3.66∗ P < 0.001
PaCO2 (mmHg) 34.84 ± 4.58 30.23 ± 4.93∗ P = 0.015 29.57 ± 3.76∗ P = 0.016 29.05 ± 3.73∗ P = 0.001
Bicarbonate (mmol/L) 23.24 ± 2.69 20.99 ± 3.08 P = 0.417 19.48 ± 2.01∗ P = 0.043 19.69 ± 2.80∗† P = 0.021
Base excess (mmol/L) −1.20 ± 2.78 −3.00 ± 3.08 P = 1.000 −4.78 ± 1.86 P = 0.077 −4.50 ± 3.07† P = 1.000
pH 7.43 ± 0.02 7.45 ± 0.02 P = 0.879 7.43 ± 0.02† P = 1.000 7.44 ± 0.02 P = 1.000
Changes in arterial blood values with ascent. The exact p-value comparing each altitude to baseline is provided. ∗ = denotes statistical significance from 1045/1400 m.
† = Statistical significance from 3440 m. Presented as mean ± SD.
Arterial blood draws were taken and assessed using a blood
gas analyzer (Abbott iStat, CG4+ and CHEM 8+ cartridges;
Mississauga, Ontario, Canada; blood gasses corrected for altitude
and body temperature; see Table 2). Each participant filled out
the Lake Louise AMS questionnaire to assess self-reported AMS
symptoms (see Table 1).
TCD Instrumentation
A non-invasive measurement of instantaneous HR was obtained
using an ECG (lead II configuration; ADInstruments Bioamp
ML132; Colorado Springs, CO, United States). PCAv was
measured using a Spencer Technologies 2 Mhz TCD (model
MD150B; Redmond, WA, United States) using standardized
procedures for vessel identification (see Willie et al., 2011).
NVC was tested using VS (iPhone “Strobe Light” app). Data
was recorded, and later analyzed offline using the PowerLab
software (v8.0) provided by ADInstruments (model 16SP
ML880) and LabChart Pro software 8.0 (Colorado Springs CO,
United States).
Experimental Protocol
NVC Protocol
Immediately after daily measures had been completed
participants reported to the designated room for NVC testing.
Participants were tested in a quiet and dark room in a seated
position. The duration of the study protocol was approximately
30 min. Participants were first instrumented with the ECG in lead
II configuration. A pulse oximeter was placed on the participant’s
finger to measure beat-by-beat peripheral oxyhemoglobin
saturation for the duration of the protocol. The TCD headpiece
was fixed on the participant’s head to a comfort level determined
by the participant. The headpiece was utilized to avoid probe
movement during the protocol. Ultrasound probes were fixed
at either side of the participant’s head on the trans-temporal
window. The trans-temporal window is located approximately
1 cm in front of the external auditory meatus and roughly
1–2 cm above the zygomatic arch. The P2 segment of the PCA
was insonated and monitored throughout. Standard methods
for determining the PCA vessel were applied prior to beginning
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the study (e.g., vessel depth and resting velocity, flow direction,
visual responsiveness and carotid compression; Willie et al.,
2011). Following set-up, the participant sat in a resting state
with the room lights switched off and eyes closed for a period of
3 min. This period formed the basis of baseline PCAv measures.
Following the 3-min baseline period, NVC was assessed via a
standardized VS (strobe light; 6 Hz). The strobe light (iPhone
application “Strobe light”) was placed approximately six inches
in front of the participant’s eyes. Participants were exposed
to three consecutive trials of VS (30 s on eyes open/30 s off
eyes closed). Participants were monitored continuously to
ensure that their eyes remained open during VS. Once VS had
been completed this signaled the end of the NVC assessment.
This protocol was repeated at each altitude, using the same
vessel. Original recordings for each individual NVC response
during VS for each participant at all four altitudes is shown in
Figure 2.
Arterial Blood Draws
Arterial blood samples were obtained from the radial artery
by a trained and registered Respiratory Therapist (HN) using
standard procedures and universal precautions. Blood samples
were collected with the participant in the supine position.
Data and Statistical Analysis
Daily Measures, Arterial Blood Draws, PCAv and NVC
Daily measures (HR, SBP, DBP, MAP, PETCO2, and SpO2) were
recorded as absolute values and compared between locations.
Similarly, values for PaO2, SaO2, PaCO2, arterial [HCO3−],
base excess and arterial blood pH were taken as absolute
values and compared between locations. AMS scores (Roach
et al., 1993) were recorded at each location and are presented
as median (range) (see Table 1). Approximate atmospheric
pressure (PATM) at each altitude was obtained online1 (Baillie,
2010) with partial pressure of inspired O2 (PIO2) calculated
by multiplying PATM by 0.21. Baseline PCAv was taken
as an average across a 3-min period immediately prior to
NVC testing. Baseline total area under the curve for PCAv
(PCAv tAUC) was calculated across a 30-s period immediately
prior to the onset of NVC assessment. To assess for any
baseline drift during the protocol, comparisons were made
both for PCAv and PCAv tAUC between baseline and the rest
periods between trials. No significant differences were found
for either baseline PCAv or PCAv tAUC between the pre-
trial baseline and the rest periods between trials (P > 0.05).
Three separate parameters were used to quantify the NVC
response. First, the mean PCAv achieved during the entirety of
each 30 s VS was calculated, averaged across the three trials
and then compared with baseline PCAv. This was ascribed
1Mean PCAv. Second, the peak PCAv achieved during each
VS was identified, averaged across the three trials and then
compared with baseline PCAv; this was ascribed 1Peak PCAv.
Finally, PCAv tAUC achieved during each VS was calculated,
averaged across the three trials and compared with baseline
PCAv tAUC. This was ascribed 1PCAv tAUC. The NVC
1http://altitude.org/
response is presented both as absolute change from baseline
and percentage increase from baseline. This methodological
approach was replicated and compared between altitudes.
Furthermore, to ensure that the NVC response was evoked
at each altitude, we present comparisons for each of the
defined parameters of NVC at baseline and during each
individual VS.
Statistical Analysis
All data were analyzed and compared using SPSS (IBM statistics,
version 24.0). Data were first tested for normal distribution
and sphericity using the Shapiro–Wilk test and Mauchly’s test
of sphericity, respectively. In situations of normal distribution,
between- and within-location comparisons were made using
a one-factor repeated measure analysis of variance (ANOVA)
with a Bonferroni post hoc adjustment. Statistical significance
was assumed at P < 0.05. When the assumption of normal
distribution was violated, a non-parametric Friedman test of
differences among repeated measures was conducted with a
Wilcoxon rank test post hoc analysis between and within
locations. Statistical significance was set at P < 0.05 divided by
the number of comparisons made.
RESULTS
Demographics and Daily Measures
Analysis revealed no significant effect of altitude on weight,
BMI and HR (P > 0.05, see Table 1). Further analysis revealed
a significant effect of altitude on SBP (F1.891,17.017 = 3.232,
P = 0.067 NP2 = 0.264), where SBP was significantly higher at
4240 m, compared with 1400 m (119 ± 11 vs. 113 ± 11 mmHg,
mean ± SD, respectively; P < 0.001; see Table 1). A significant
effect of altitude was observed for DBP (F3,27 = 19.39, P < 0.001
NP2 = 0.683), with DBP being significantly elevated at 3440,
3820, and 4240 m compared with 1400 m (87 ± 8, 90 ± 10
and 87 ± 9 vs. 78 ± 11 mmHg, respectively; P < 0.001,
P = 0.002, and P < 0.001, respectively; see Table 1). Similarly, a
significant effect of altitude was observed in MAP (F3,27 = 13.613,
P < 0.001 NP2 = 0.602). MAP was elevated at 3440, 3820,
and 4240 m compared with 1400 m (96 ± 7, 100 ± 10, and
98 ± 9 vs. 89 ± 11 mmHg, respectively; P = 0.026, P = 0.006,
and P < 0.001, respectively; see Table 1). A significant effect
of altitude was observed in (PET)CO2 (F1.246,11.214 = 25.012,
P< 0.001NP2 = 0.735). (PET)CO2 was significantly lower at 3440,
3820, and 4240 m compared with 1400 m (26.5± 3.0, 25.3± 2.7,
and 21.1 ± 1.9 vs. 32.6 ± 6.8 Torr, respectively; P = 0.043,
P = 0.018, and P< 0.001, respectively; see Table 1). Furthermore,
(PET)CO2 was significantly lower at 4240 m compared with both
3440 and 3820 m (P < 0.001 and P < 0.001, respectively).
Finally, a significant effect of altitude was observed for SpO2
[X2(3) = 25.906, P < 0.001]. SpO2 was significantly lower at
3440, 3820, and 4240 m compared with 1400 m (91.80 ± 2.49,
91.40 ± 2.84, and 87.60 ± 2.01 vs. 96.40 ± 0.97%, respectively;
P = 0.005, P = 0.005, and P = 0.005, respectively; see Table 1).
Furthermore, SpO2 was significantly lower at 4240 m compared
with 3440 m (P = 0.008).
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FIGURE 2 | Individual mean PCAv. Original tracings of derived mean PCAv for each participant, during each visual stimulation (VS) trial, at each altitude are provided.
Mean PCAv is presented along the y-axis with time presented along the x-axis. Gray shaded regions denote thirty second periods of VS.
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FIGURE 3 | Arterial blood gas and acid-base data. Ascent to high altitude (HA) had a significant effect on (A) PaO2 (P < 0.001), (B) SaO2 (P < 0.032), (C) PaCO2
(P < 0.016), (D) arterial bicarbonate [HCO3−] (P < 0.043). Compared with baseline, ascent to HA had no significant effect on (E) base excess (P > 0.05) and (F)
arterial pH (P > 0.05). ∗ = denotes statistical significance from 1045/1400 m. † = Statistical significance from 3440 m. Presented as scatter plots representing
individual participants with box and whiskers showing median, 25–75 percentile with minimum and maximum values.
Arterial Blood Gas and Acid-Base Status
Analysis revealed a statistically significant effect of altitude
on PaO2 (F3,18 = 138.270, P < 0.001 Np2 = 0.958). PaO2
was significantly lower at 3440, 3820, and 4240 m compared
with 1045/1400 m (48.5 ± 8.1, 54.6 ± 6.2, 48.4 ± 5.0 vs.
84.8 ± 5.4 mmHg, respectively; P < 0.001, P < 0.001, and
P < 0.001, respectively; see Figure 3A). A statistically significant
effect of altitude on SaO2 (F3,18 = 17.313, P < 0.001 Np2 = .743).
SaO2 was significantly lower at 3440, 3820, and 4240 m compared
with 1045/1400 m (84.9 ± 7.9, 88.8 ± 3.7, 85.5 ± 3.7 vs.
96.8 ± 0.8%, respectively; P = 0.032, P = 0.003, and P < 0.001,
respectively; see Figure 3B). A statistically significant effect of
altitude on PaCO2 (F3,18 = 23.123, P < 0.001 Np2 = 0.794).
PaCO2 was significantly lower at 3440, 3820, and 4240 m
compared with 1045/1400 m (30.2 ± 4.9, 29.6 ± 3.8, 29.1 ± 3.7
vs. 34.8 ± 4.6 mmHg, respectively; P = 0.015, P = 0.016, and
P < 0.001, respectively; see Figure 3C). A statistically significant
effect of altitude on [HCO3−] (F3,18 = 11.342, P < 0.001,
Np2 = 0.654). [HCO3−] was significantly lower at 3820 and
4240 m compared with 1045/1400 m (19.5 ± 2.0, 19.7 ± 2.8
vs. 23.2 ± 2.7 mmol/L, respectively; P = 0.043 and P = 0.021,
respectively; see Figure 3D). No significant differences were
found between 1045/1400 m and 3440 m for [HCO3−] (23.2± 2.7
vs. 21.0 ± 3.1 mmol/L, respectively; P = 0.417), but a significant
difference for [HCO3−] was found between 3440 and 4240 m
(P = 0.006). A statistically significant effect of altitude on base
excess (F3,18 = 7.132, P = 0.002, Np2 = 0.543). Base excess
was significantly lower at 4240 m compared with 3440 m
(−4.143 ± 1.18 vs. −2.286 ± 1.19 mmol/L, respectively;
P = 0.022; see Figure 3E). Analysis observed no statistically
significant effect of altitude on arterial pH when compared with
baseline (F3,18 = 2.788, P = 0.070 Np2 = 0.317; see Figure 3F).
Baseline PCAv and PCAv tAUC
Comparisons
There were no significant differences for baseline PCAv or
baseline PCAv tAUC between locations [X2(3) = 5.640, P = 0.131
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FIGURE 4 | Cerebral blood velocity. Data for posterior cerebral artery velocity (PCAv) during baseline recording. Ascent to HA had no significant effect on (A)
baseline PCAv (P > 0.131) and (B) baseline PCAv total area under the curve (tAUC) (P > 0.086). Presented as scatter plots representing individual participants with
box and whiskers showing median, 25–75 percentile with minimum and maximum values.
FIGURE 5 | Mean PCAv response. Comparison of the mean PCAv achieved during baseline (BL) and during each individual VS at each altitude. Significant
differences were found between BL PCAv and mean PCAv during VS at (A) 1045 m (P < 0.003), (B) 3440 m (P < 0.010), (C) 3820 m (P < 0.005), and (D) 4240 m
(P < 0.007). ∗ = Statistical significance from BL. † = Statistical significance from VS 1. Presented as scatter plots representing individual participants with box and
whiskers showing median, 25–75 percentile with minimum and maximum values.
and X2(3) = 6.60, P = 0.086, respectively; see Figures 4A,B,
respectively].
NVC Response (1Mean PCAv, 1Peak
PCAv or 1PCAv tAUC)
We first sought to assert that the NVC response was evoked at
each location. We therefore compared the absolute mean and
peak PCAv achieved during each individual VS to baseline PCAv.
We replicated this analysis for PCAv tAUC, thus covering all
three NVC parameters.
1045 m
A significant effect was found between baseline and VS for
mean PCAv, peak PCAv, and PCAv tAUC (F1.5,13.503 = 29.151,
P < 0.001, Np2 = 0.764; F3,27 = 42.513, P < 0.001, Np2 = 0.825;
F3,27 = 15.847, P < 0.001, Np2 = 0.638, respectively). Further
analysis revealed that mean PCAv, peak PCAv, and PCAv tAUC
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FIGURE 6 | Peak PCAv response. Comparison of the mean PCAv during BL and peak PCAv during each individual VS. Significant differences were found between
BL PCAv and peak PCAv during VS at (A) 1045 (P < 0.001), (B) 3440 m (P < 0.001), (C) 3820 m (P < 0.007), and (D) 4240 m (P < 0.005). ∗ = Statistical
significance from BL. † = Statistical significance from VS 1. Presented as scatter plots representing individual participants with box and whiskers showing median,
25–75 percentile with minimum and maximum values.
were statistically different during each individual VS compared
with baseline (P < 0.003, P < 0.001, and P < 0.006, respectively;
see Figures 5A, 6A, 7A).
3440 m
A significant effect was found between baseline and VS for
mean PCAv, peak PCAv and PCAv tAUC (F1.385,12.466 = 20.913,
P < 0.001, Np2 = 0.699; F1.414,12.723 = 48.820, P < 0.001,
Np2 = 0.844; F3,27 = 22.749, P< 0.001, Np2 = 0.717, respectively).
Further analysis revealed that mean PCAv, peak PCAv, and
PCAv tAUC were statistically different during each individual VS
compared with baseline (P < 0.010, P < 0.001, and P = 0.003,
respectively; see Figures 5B, 6B, 7B). Additionally, post hoc
analysis found a statistically significant difference between mean
PCAv during VS 1 and VS 2 (P = 0.034). Furthermore, a
statistically significant difference was observed between peak
PCAv during VS 1 compared with VS 2 and VS 3 (P = 0.027 and
P = 0.016, respectively).
3820 m
There was a statistically significant effect observed for mean
PCAv, peak PCAv, and PCAv tAUC between baseline and
VS [X2(3) = 16.80, P < 0.001; X2(3) = 17.64, P < 0.001;
and X2(3) = 15.00, P = 0.002, respectively]. Further analysis
revealed that mean PCAv was significantly higher during
VS 2 and VS 3 compared with baseline (BL) (P = 0.005,
P = 0.005, respectively; see Figure 5C) and that peak PCAv
was significantly higher during each VS trial compared with
BL (P < 0.007; see Figure 6C). PCAv tAUC was significantly
higher during VS 3 only, compared with BL (P = 0.005; see
Figure 7C).
4240 m
There was a statistically significant effect observed for mean
PCAv, peak PCAv, and PCAv tAUC between baseline and VS
[X2(3) = 16.44, P < 0.001; X2(3) = 19.56, P < 0.001; and
X2(3) = 20.52, P < 0.001, respectively]. Post hoc analysis revealed
that mean PCAv was significantly higher during VS 1 and VS 2
compared with baseline (BL) (P = 0.005, P = 0.007, respectively;
see Figure 5D). Additionally, peak PCAv was significantly
higher during each VS trial compared with BL (P < 0.005; see
Figure 6D). PCAv tAUC was significantly higher during VS 1 and
VS 2 compared with BL (P = 0.005, P = 0.005, respectively; see
Figure 7D). Furthermore, post hoc analysis revealed a significant
effect between VS 1 and VS 2 for PCAv tAUC (P = 0.007).
Between Location NVC Comparison
There was no significant effect of altitude on either 1mean
PCAv, 1peak PCAv, or 1PCAv tAUC (F3,27 = 1.948, P = 0.146,
Np2 = 0.178, F3,27 = 1.948, P = 0.045, Np2 = 0.254 and
F3,27 = 1.384, P = 0.269, Np2 = 0.133, respectively; see
Figures 8A–C, respectively).
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FIGURE 7 | PCAv tAUC response. Comparison of the posterior cerebral artery velocity total area under the curve (PCAv tAUC) achieved during BL and PCAv tAUC
during each individual VS. Significant differences were found between BL PCAv tAUC and PCAv tAUC during VS at (A) 1045 m (P < 0.006), (B) 3440 m (P < 0.003),
(C) 3820 m (P = 0.005), and (D) 4240 m (P < 0.005). ∗ = Statistical significance from BL. † = Statistical significance from VS 1. Presented as scatter plots
representing individual participants with box and whiskers showing median, 25–75 percentile with minimum and maximum values.
DISCUSSION
Primary Findings
This study investigated the influence of incremental ascent to
4240 m over 7 days on NVC. Our results demonstrate: (1) the
NVC response was evoked consistently at each altitude, and (2)
there was no significant difference in the magnitude of the NVC
response at the level of the PCA between altitudes in healthy
acclimatized individuals.
Acclimatization
Exposure to HA and the associated drop in total barometric
pressure induced a state of hypoxemia. This is evident from
the significant decreases in PaO2 and SaO2 (see Figures 3A,B).
During prolonged exposure to HA, hypoxia increases activation
of the peripheral chemoreceptors, enhancing the HVR (Ainslie
and Ogoh, 2010; Willie et al., 2015; Hoiland et al., 2016). The
HVR increases ventilatory drive partially restoring PaO2 and
SaO2 levels toward resting values (Bernardi et al., 2006; Smith
et al., 2014). Comparing values recorded at 3440m with those
obtained at higher altitudes, with further decreases in barometric
pressure, we observed no further reductions in PaO2 and
SaO2, revealing attenuation of a further decline in oxygenation
associated with continued ascent.
Secondly, we observed profound hypocapnia, as demonstrated
by significant decreases in PaCO2, indicative of hyperventilation
(see Figure 3C). Hypocapnia serves to blunt both central and
peripheral chemoreceptor activation and subsequently reduces
ventilatory drive. Combined, these data reveal the presence of
two antagonistic vasoactive stressors: hypoxia and hypocapnia.
Hypoxia, below a threshold (<40–45 mmHg), has a vasodilatory
effect in the systemic circuit (Ainslie and Ogoh, 2010). In
contrast, hypocapnia is a potent vasoconstrictor (Brugniaux
et al., 2007). The cerebrovasculature is particularly sensitive
to changes in ABGs, especially PaCO2 (Brugniaux et al.,
2007; Ainslie and Ogoh, 2010). Although prior research has
shown that the presence of hypocapnia decreases the NVC
response (Szabo et al., 2011), this study was laboratory-based
and did not include the hypoxic vasodilatory stress associated
with HA. Furthermore, the presence of sustained hypocapnia
presents further issues by inducing tissue alkalosis (Krapf et al.,
1991).
Hyperventilation-induced hypocapnia triggers an acid-base
adjustment in the form of renal compensation. To counteract
respiratory alkalosis, and maintain pH within normal limits,
a series of compensatory steps are required through increased
acid retention coupled with an increase in HCO3− excretion
via the renal system (Zouboules et al., 2018). The end-product
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FIGURE 8 | Neurovascular coupling (NVC) response. Comparison of the NVC response for 1mean PCAv, 1peak PCAv, and 1PCAv tAUC between altitudes. The
magnitude of the response is presented as both the respective 1 from baseline (left column), and the corresponding percentage change from baseline (right
column). No significant differences were found for (A)1mean PCAv (P > 0.05), (B)1peak PCAv (P > 0.05), (C)1PCAv tAUC (P > 0.05). Presented as scatter plots
representing individual participants with box and whiskers showing median, 25–75 percentile with minimum and maximum values.
of a relative metabolic acidosis helps to decrease arterial pH
toward normal values, thereby preserving acid-base homeostasis
(Goldfarb-Rumyantzev and Alper, 2014). The sophisticated and
refined nature of this compensatory adaptation is crucial as
the vasoconstrictive effects of hypocapnia/alkalosis can decrease
CBF (Szabo et al., 2011). Furthermore, a blunted HVR response
has been shown to be a strong predictor of AMS (Richalet
et al., 2012). We observed evidence of renal compensation
by way of significant decreases in arterial [HCO3−] (see
Figure 3D) in response to hypocapnia, such that arterial
pH was maintained constant throughout ascent compared
with BL.
Impact of HA on CBF and NVC
We found no significant differences in baseline PCAv and
baseline PCAv tAUC during ascent (Figure 4). In terms of NVC,
we observed that for each of our designated NVC parameters,
a significant response was evoked during VS (see Figures 5–7).
Our results demonstrate the remarkable reproducibility of the
within-group NVC response. For between-altitude comparisons,
our findings demonstrate that NVC remained intact at the level of
the PCA, as demonstrated by no significant differences in each of
the three NVC response parameters between altitudes (Figure 8),
although we observed both inter-subject variability of the NVC
response and intra-subject variability in the NVC response
between altitudes (Figure 2). These findings are consistent with
a previous study (Caldwell et al., 2017), where NVC testing
was performed temporally in response to acclimatization at a
single altitude. These studies differed in terms of ascent-profile,
altitude reached, analysis and stimulus to evoke NVC. However,
the finding that NVC remains intact during ascent to HA is
consistent.
Methodological Limitations
The utilization of TCD for the assessment of CBF has limitations.
Although TCD provides excellent beat-by-beat measurement
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of the intracranial arteries arising from the circle of Willis, it
does not provide any indication of pre-existing diameter of
the insonated vessel. This is relevant at HA where there are
multiple and competing stressors, which influence vessel tone
(hypoxic vasodilation and hypocapnic vasoconstriction). There
is also recent literature to suggest that there are stimulus-evoked
changes in diameter of the PCA as a function of distance
from the primary visual cortex (Bizeau et al., 2017). There is
therefore an inherent risk of misinterpreting the magnitude of
the CBF change (Caldwell et al., 2017). Furthermore, there is
a risk of technical error given the sensitivity of transcranial
Doppler technique. To account for this, we ensured the same
sonographers were present during each testing session. We also
strictly abided by a set of guidelines for insonating the PCA (see
Willie et al., 2011). We also acknowledge that TCD provides
measurements of velocity rather than flow. However, recent
literature has demonstrated CBF velocity to be an appropriate
and reliable surrogate for CBF (Secher et al., 2008; Ainslie and
Ogoh, 2010). Although our findings demonstrate an intact NVC
response during incremental ascent to HA, further research
is required to fully explore this issue. The cerebrovasculature
can be subdivided into three categories: large pial arteries
which run along the surface of the cortex (i.e., PCA), pial
arterioles which penetrate the cortex and finally parenchymal
arterioles and capillaries (Filosa et al., 2016; Phillips et al.,
2016). It has been postulated that NVC-mediated responses
are initiated within the parenchymal arterioles and capillaries
(Filosa et al., 2016). Whether the NVC response within the
microvasculature is affected during incremental ascent to HA
remains unknown. Although we did not directly measure the
NVC response at the microvascular level, the application of
TCD to conduit arteries for assessment of NVC in human
volunteers is a well-established technique (Willie et al., 2011;
Phillips et al., 2016). If the diameter of the PCA was increased
during VS, this would have evoked a blunted hyperemic response,
that is the increase in PCA diameter would have caused a
reduction in PCAv (Phillips et al., 2016). As this was not
observed in our study, we assume a constant PCA diameter
during VS, with the increase in PCAv most likely due to
downstream vasodilation at the level of the neurovascular
unit.
CONCLUSION
As expected, exposure to HA elicited an incremental state
of hypoxic hypocapnia. However, respiratory alkalosis was
adequately combatted via renal compensation (relative metabolic
acidosis), preserving arterial pH within normal limits during the
ascent profile. Despite the combination of stressors associated
with incremental ascent to 4240 m, NVC remains remarkably
intact through the PCA. We postulate that during exposure
to HA, NVC could be predominantly sensitive to arterial pH.
This study highlights the remarkable innate ability of the
cerebrovasculature to adapt to environmental stress through
a series of integrative adaptations, with several intrinsically
complex systems working in unison to preserve cerebrovascular
homeostasis and function. Strengths of this study include
the comprehensive manner by which the NVC response was
presented, analyzed and compared at each altitude. Although we
tested NVC at a higher altitude than that employed in previous
studies (Caldwell et al., 2017), future studies might incorporate
even higher altitudes where HA illness symptomology becomes
increasingly prevalent. Whereas our study demonstrates that
NVC remains intact during incremental ascent to 4240 m
in acclimatized volunteers, it is plausible to suggest that
responses may be impaired in unacclimatized individuals, during
rapid ascent, or perhaps at altitudes higher than 4240 m.
It would be interesting to investigate the temporal effects of
exposure to HA on NVC, both in the acute and chronic
setting.
It will also be important to investigate in other experimental
models the effects of chronic hypobaric hypoxia on the
NVC response within sub-cortical parenchymal arterioles and
capillaries, which is not feasible in field studies at high altitude
in humans.
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